<DOC>
	<DOCNO>NCT02907281</DOCNO>
	<brief_summary>This 3-year , pharmacologically non-interventional study evaluate OCT outcome measure patient relapse remit multiple sclerosis ( RRMS ) . Approximately 350 RRMS patient , either untreated treat approved MS disease-modifying therapy approximately 70 reference subject without ophthalmologic neurologic disease enrol . No study medication provide . Patients disease-modifying therapy treat accord local prescribing information . For MS patient reference subject , study consist Screening ( 1 month ) , Baseline , 36-month longitudinal data collection phase . Eligibility confirm Screening .</brief_summary>
	<brief_title>Optical Coherence Tomography ( OCT ) Trial Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Multiple sclerosis patient A diagnosis MS define 2005 revision McDonald criterion relapsingremitting course MS disease duration one year ( diagnosis MS ) study entry Healthy volunteer Matched MS patient base age , gender , ethnicity visual refraction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>Optical coherence tomography</keyword>
	<keyword>OCT</keyword>
	<keyword>RRMS</keyword>
</DOC>